Russell Investments Group Ltd. Sells 40,593 Shares of Hologic, Inc. (NASDAQ:HOLX)

Russell Investments Group Ltd. decreased its stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 17.1% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 197,058 shares of the medical equipment provider's stock after selling 40,593 shares during the period. Russell Investments Group Ltd. owned 0.08% of Hologic worth $14,074,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Qube Research & Technologies Ltd increased its position in Hologic by 117.2% in the 3rd quarter. Qube Research & Technologies Ltd now owns 1,378,258 shares of the medical equipment provider's stock worth $95,651,000 after buying an additional 743,557 shares during the period. Jennison Associates LLC bought a new stake in Hologic in the 4th quarter valued at $30,079,000. Assenagon Asset Management S.A. grew its position in Hologic by 90.4% in the 3rd quarter. Assenagon Asset Management S.A. now owns 845,493 shares of the medical equipment provider's stock worth $58,677,000 after purchasing an additional 401,486 shares during the last quarter. Victory Capital Management Inc. increased its holdings in shares of Hologic by 8.9% during the 3rd quarter. Victory Capital Management Inc. now owns 4,838,090 shares of the medical equipment provider's stock worth $335,763,000 after purchasing an additional 393,371 shares during the period. Finally, Clearbridge Investments LLC bought a new stake in shares of Hologic in the third quarter valued at about $25,398,000. Institutional investors and hedge funds own 94.73% of the company's stock.

Hologic Price Performance

Shares of NASDAQ HOLX traded up $0.63 during mid-day trading on Friday, hitting $76.54. 2,069,424 shares of the stock were exchanged, compared to its average volume of 1,449,410. The company has a market cap of $17.97 billion, a P/E ratio of 39.05, a PEG ratio of 2.56 and a beta of 1.01. The company has a debt-to-equity ratio of 0.55, a quick ratio of 3.18 and a current ratio of 3.89. Hologic, Inc. has a twelve month low of $64.02 and a twelve month high of $86.74. The stock's fifty day simple moving average is $76.13 and its two-hundred day simple moving average is $73.02.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings results on Thursday, May 2nd. The medical equipment provider reported $1.03 earnings per share for the quarter, beating analysts' consensus estimates of $0.98 by $0.05. The firm had revenue of $1.02 billion during the quarter, compared to analysts' expectations of $1 billion. Hologic had a return on equity of 18.81% and a net margin of 11.78%. The business's revenue was down .8% on a year-over-year basis. During the same period last year, the firm posted $1.06 EPS. As a group, analysts forecast that Hologic, Inc. will post 4.02 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have commented on the company. Needham & Company LLC reaffirmed a "buy" rating and issued a $90.00 price target on shares of Hologic in a report on Friday. UBS Group boosted their price target on shares of Hologic from $78.00 to $79.00 and gave the company a "neutral" rating in a report on Friday, February 2nd. Citigroup raised shares of Hologic from a "neutral" rating to a "buy" rating and raised their price objective for the stock from $80.00 to $95.00 in a report on Wednesday, April 3rd. William Blair reissued an "outperform" rating on shares of Hologic in a research note on Friday, February 2nd. Finally, Evercore ISI raised their price target on shares of Hologic from $76.00 to $78.00 and gave the stock an "in-line" rating in a research note on Thursday, April 4th. Five analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to MarketBeat, Hologic presently has an average rating of "Moderate Buy" and a consensus target price of $84.56.

Insiders Place Their Bets

In other Hologic news, Director Charles J. Dockendorff sold 1,465 shares of the business's stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $76.21, for a total value of $111,647.65. Following the completion of the transaction, the director now directly owns 1,572 shares of the company's stock, valued at $119,802.12. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, Director Scott T. Garrett sold 16,441 shares of the company's stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $75.50, for a total transaction of $1,241,295.50. Following the transaction, the director now owns 48,611 shares of the company's stock, valued at $3,670,130.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Charles J. Dockendorff sold 1,465 shares of Hologic stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $76.21, for a total value of $111,647.65. Following the completion of the sale, the director now owns 1,572 shares of the company's stock, valued at $119,802.12. The disclosure for this sale can be found here. Insiders own 1.75% of the company's stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.